Articles related to ADDICTION MEDICINE

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

“The amygdala’s response to social threat appears to feed into depressive symptoms much more strongly in young males than in young females.” — John Krystal, MD, Biological Psychiatry

Note that many questions remain after this trial returned results that are not unequivocally positive. The prespecified primary outcome was negative, which limits claims of efficacy and argues against overinterpreting the study as confirmatory evidence for psilocybin in treatment-resistant depression.

“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors

“The prevalence of internalizing problems increased more rapidly among Canadians who used cannabis compared to those who do not.” — Study authors

The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.